Patents Assigned to Pfizer Inc.
  • GLP-1 RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20210047298
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 18, 2021
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, Matthew S. Dowling, David Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Gajendra Ingle, Wenhua Jiao, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • capsular polysaccharides and conjugates thereof
    Patent number: 10918708
    Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: February 16, 2021
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF
    Publication number: 20210040045
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Application
    Filed: May 28, 2020
    Publication date: February 11, 2021
    Applicant: Pfizer Inc.
    Inventors: Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
  • Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
    Patent number: 10906888
    Abstract: Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 2, 2021
    Assignee: Pfizer Inc.
    Inventors: Agustin Casimiro-Garcia, Joseph Walter Strohbach, David Hepworth, Frank Eldridge Lovering, Chulho Choi, Christophe Philippe Allais, Stephen Wayne Wright
  • Recombinant ROBO2 proteins, compositions, methods and uses thereof
    Patent number: 10906955
    Abstract: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 2, 2021
    Assignees: Pfizer Inc., Boston Medical Center Corporation
    Inventors: Stephen Berasi, Janet Elizabeth Buhlmann, Nathan Higginson-Scott, Michael Shamashkin, Matthew Russo, Stefano V. Gulla, Zong Sean Juo, Sreekumar R. Kodangattil, Weining Lu, Xueping Fan, David J. Salant
  • METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY IN COMBINATION WITH 4-1BB AGONIST
    Publication number: 20210023134
    Abstract: The disclosure provides a method of treatment of a B-cell lymphoma or leukemia, including diffuse large B-cell lymphoma (DLBCL) comprising a CD19-directed chimeric antigen receptor (CAR) genetically modified T-cell immunotherapy in combination with a 4-IBB (CD137) agonist. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T-cell therapy provided herein.
    Type: Application
    Filed: January 15, 2019
    Publication date: January 28, 2021
    Applicants: Pfizer Inc., Kite Pharma, Inc.
    Inventors: William Y. GO, Adrian WOOLFSON
  • RSV F Protein Mutants
    Publication number: 20210023200
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: Pfizer Inc.
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF
    Publication number: 20210023193
    Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang
  • BCKDK INHIBITORS
    Publication number: 20210024536
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Application
    Filed: June 26, 2020
    Publication date: January 28, 2021
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Leanne Marie Buzon, Kevin James Filipski, David Andrew Griffith, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • compositions and methods thereof
    Patent number: 10899802
    Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: January 26, 2021
    Assignee: PFIZER INC.
    Inventors: Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Kathrin Ute Jansen, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
  • Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
    Patent number: 10899840
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 26, 2021
    Assignees: Pfizer Inc., Merck Sharp & Dohme Corp.
    Inventors: Craig Bennett Davis, Maria Theresa Koehler, Li Yan
  • TOLL-LIKE RECEPTOR AGONISTS
    Publication number: 20210017172
    Abstract: The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: July 13, 2020
    Publication date: January 21, 2021
    Applicant: Pfizer Inc.
    Inventors: Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
  • Fluoro-Pyridinone Phosphates And Boronates Useful As Antibacterial Agents
    Publication number: 20210017205
    Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O?M+), —P(O)(O?M+)2 and —P(O)(O?)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 21, 2021
    Applicant: Pfizer Inc.
    Inventors: Tamim Fehme Braish, Matthew Frank Brown, Ye Che, Richard Andrew Ewin, Timothy Allan Johnson, Michael Joseph Melnick, Justin Ian Montgomery, Mark Stephen Plummer, Loren Michael Price, Usa Reilly, Daniel Uccello
  • Antibody Purification
    Publication number: 20210017254
    Abstract: Methods for the purification of antibodies are provided. Purification methods provided involve the use of hydroxyapatite resin (HA) to separate an antibody of interest from one or more impurities. The impurity may be a clipped antibody that comprises a cleaved peptide bind in the VH domain.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 21, 2021
    Applicant: PFIZER INC.
    Inventors: Timothy ISKRA, Ashley Margaret SACRAMO
  • CELLS AND METHOD OF CELL CULTURE
    Publication number: 20210017553
    Abstract: The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. The invention further relates to a method of producing cells with improved cell growth and/or productivity in cell culture and to cells obtained or obtainable by such methods.
    Type: Application
    Filed: June 30, 2020
    Publication date: January 21, 2021
    Applicant: PFIZER INC.
    Inventors: Gregory Walter HILLER, Jeffrey Joseph MITCHELL, Bhanu Chandra MULUKUTLA, Pamela Mary PEGMAN
  • Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation
    Patent number: 10894083
    Abstract: The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-vascular endothelial growth factor (VEGF) antibody.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: January 19, 2021
    Assignee: Pfizer Inc.
    Inventors: Rebecca Lee Ingram, Sarah Elizabeth Weiser
  • SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS
    Publication number: 20210009657
    Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
    Type: Application
    Filed: February 20, 2020
    Publication date: January 14, 2021
    Applicants: Pfizer Inc., INSERM (Institut National de la Sante et de la Recherche Medicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF
    Publication number: 20210009601
    Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
    Type: Application
    Filed: September 29, 2020
    Publication date: January 14, 2021
    Applicant: Pfizer Inc.
    Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
  • compositions and methods thereof
    Patent number: 10888611
    Abstract: In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 ?g/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 ?g/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: January 12, 2021
    Assignee: PFIZER INC.
    Inventors: Kathrin Ute Jansen, Annaliesa Sybil Anderson, Rasappa Gounder Arumugham, John Erwin Farley, Leah Diane Fletcher, Shannon Lea Harris, Thomas Richard Jones, Lakshmi Khandke, Bounthon Loun, John Lance Perez, Gary Warren Zlotnick
  • Bruton's Tyrosine Kinase Inhibitors
    Publication number: 20210002251
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 7, 2021
    Applicant: Pfizer Inc.
    Inventors: John Robert Springer, Balekudru Devadas, Danny James Garland, Margaret Lanahan Grapperhaus, Seungil Han, Susan Landis Hockerman, Robert Owen Hughes, Eddine Saiah, Mark Edward Schnute, Shaun Raj Selness, Daniel Patrick Walker, Zhao-Kui Wan, Li Xing, Christoph Wolfgang Zapf, Michelle Ann Schmidt